ENTBF News and Press, Entheon Biomedical Corp Com From 08/12/21

EEG Study to be incorporated into Entheon IQ(TM), developing data-driven treatment algorithms for psychedelic treatments Vancouver, British Columbia--(Newsfile Corp. - August 12, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) (" Entheon " or the " Company "), a biotec...

Entheon Biomedical (OTCQB:ENTBF) completed the acquisition of Lobo Genetics in a stock deal. Lobo is a genetics company with a direct-to-consumer platform, used in the psychedelics and cannabis spaces to provide personalized insights into an individual's response to hallucinogenic and psychoa...

Genetic Screening Platform Technology and Data to Strengthen Entheon's Psychedelic-Assisted Protocols Vancouver, British Columbia--(Newsfile Corp. - July 30, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) (" Entheon " or the " Company ") is pleased to announce that th...

Vancouver, British Columbia--(Newsfile Corp. - July 28, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) (" Entheon " or the " Company "), a biotechnology company focused on developing psychedelic medicines to treat addiction, is pleased to announce the addition of Dr. A...

Vancouver, British Columbia--(Newsfile Corp. - June 30, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) (" Entheon " or the " Company "), a biotechnology company focused on developing psychedelic medicines to treat addiction, is pleased to announce the addition of emerg...

Entheon Biomedical is a biotech R&D company developing a portfolio of Dimethyltryptamine (DMT) based psychedelic therapeutic products for treating addiction and substance use disorders. CEO Timothy Ko talks about his personal connection to addiction, clinical trials, and evolving ...

Vancouver, British Columbia--(Newsfile Corp. - June 25, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ( "Entheon" or the "Company" ), a biotechnology company focused on developing psychedelic medicines to treat addiction, has announced an agreement with Maya health ...

To drive brand awareness of, and access to, HaluGen's Psychedelics Genetic Test Kit Vancouver, British Columbia--(Newsfile Corp. - June 22, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ("Entheon" or the "Company"), a biotechnology company focused on developing psych...

Entheon Biomedical (ENTBF) and Silo Wellness (SILFF) have signed a referral agreement to help drive brand awareness of the Psychedelics Genetic Test kit, developed and commercialized by HaluGen Life Sciences.The genetic test identifies specific DNA biomarkers in order to gauge the risk a...

Vancouver, British Columbia--(Newsfile Corp. - June 17, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ( "Entheon" ), a biotechnology company focused on developing psychedelic medicines to treat addiction, and Silo Wellness Inc. (CSE: SILO) (OTC: SILFF) (FSE:3K70) ( "S...